Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma

Barsegian, Vahé; Horn, Peter A.; Bockisch, Andreas; Lindemann, Monika

doi:10.3413/nukmed-04241108

Cited by 10 publications

(12 citation statements)

References 20 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a slightly different study design, Barsegian et al [45] analyzed the production of pro-inflammatory cytokine IFN-γ and antiinflammatory cytokine IL-10 in DTC patients treated with radioactive 131-I. Upon stimulation with microbial antigen at the single cell level (using ELISPOT assay), there was an increase of IFN-γ production in DTC patients 1 day after 131-I therapy with return to pretreatment values 7 days after therapy.…”

Section: Discussionmentioning

confidence: 97%

Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

Zivancevic-Simonovic

Mihaljevic

Majstorović

et al. 2014

Cancer Immunol Immunother

View full text Add to dashboard Cite

Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant diseases. The aim of this study was to evaluate cytokine profiles in patients with differentiated thyroid cancer (DTC) before and 7 days after radioactive iodine (131-I) therapy. Cytokine levels were determined in supernatants obtained from phytohemagglutinin-stimulated whole blood cultures of 13 patients with DTC and 13 control subjects. The concentrations of selected cytokines: Th1-interferon gamma (IFN-γ), interleukin 2 (IL-2) and tumor necrosis factor alpha (TNF-α); Th2-interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 13 (IL-13) and interleukin 10 (IL-10); Th9-interleukin-9 (IL-9); and Th17-interleukin 17 (IL-17A) were measured using multiplex cytokine detection systems for Human Th1/Th2/Th9/Th17/Th22. We have shown that peripheral blood cells of DTC patients produce significantly higher concentrations of Th2/Th9 cytokines (IL-5, IL-13 and IL-9) than control subjects. The 131-I therapy led to reduced secretion of Th2 cytokines (IL-4, IL-5 and IL-13). Despite this, the calculated cytokine ratios (Th1/Th2) in DTC patients before and 7 days after 131-I therapy were not different from those in healthy subjects. DTC patients have significantly higher concentrations of Th2/Th9 cytokines (IL-5, IL-13 and IL-9) than control subjects. There is no influence of hypothyroidism or stage of disease on cytokine production in DTC patients before 131-I therapy. The radioactive 131-I therapy leads to reduced secretion of Th2 cytokines (IL-4, IL-5 and IL-13). Additional studies are needed to determine the significance of these findings.

show abstract

Section: Discussionmentioning

confidence: 97%

Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

Zivancevic-Simonovic

Mihaljevic

Majstorović

et al. 2014

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…131 I treatment increases Treg count and decreases B lymphocyte count, leading to an immune imbalance ( 48 ). However, there has been no clinical confirmation of immunosuppressive status, implying that the clinical effects of toxicity are limited ( 49 ). 131 I treatment does not enhance the risk, morbidity, or mortality of COVID-19 ( 50 ).…”

Section: Therapeutic Approaches During the Covid-19 Pandemicmentioning

confidence: 99%

Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development

Hui

Shen

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Thyroid cancer is the most prevalent endocrine malignancy and the reported incidence of thyroid cancer has continued to increase in recent years. Since 2019, coronavirus disease 2019 (COVID-19) has been spreading worldwide in a global pandemic. COVID-19 aggravates primary illnesses and affects disease management; relevant changes include delayed diagnosis and treatment. The thyroid is an endocrine organ that is susceptible to autoimmune attack; thus, thyroid cancer after COVID-19 has gradually attracted attention. Whether COVID-19 affects the diagnosis and treatment of thyroid cancer has also attracted the attention of many researchers. This review examines the literature regarding the influence of COVID-19 on the pathogenesis, diagnosis, and treatment of thyroid cancer; it also focuses on drug therapies to promote research into strategies for improving therapy and management in thyroid cancer patients with COVID-19.

show abstract

“…These adverse events depend on the radiation dose and anatomical extension. However, most studies concluded that no clinically relevant immunosuppression is observed with conventional 131 I low activity [12,13]. Although RAI therapy is still considered a tool for the treatment of patients with differentiated thyroid carcinoma, it is advisable to undertake efforts to select the proper candidates for this therapy.…”

Section: Radioactive Iodine (Rai) Therapymentioning

confidence: 99%

Thyroid cancer in the Era of COVID-19

et al. 2020

View full text Add to dashboard Cite

The recent coronavirus infectious disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is placing health systems in serious challenges worldwide. Shocking statistics each day has prompted the World Health Organization to officially declare the COVID-19 outbreak as a pandemic in March 2020. Preliminary studies have shown increased mortality in patients with solid cancers and infection by SARS-CoV-2. Until now, the evidence on the behavior of COVID-19 in patients with a history of thyroid cancer remains scarce, and most of the recommendations given are based on common sense. Therefore, in this viewpoint, we present a brief review of several challenges we are frequently facing during this pandemic and a series of recommendations based on what we have implemented in our clinical practice at a university hospital currently mostly dedicated to COVID-19.

show abstract

Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma

Abstract: Thyroid carcinoma patients receiving radioiodine therapy do not display any sign of immunosuppression.

Cited by 10 publications

References 20 publications

Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development

Thyroid cancer in the Era of COVID-19

Contact Info

Product

Resources

About